However, HSC gene therapy to overexpress mutant methylguanine methyltransferase (MGMT) has been used for bone marrow chemoprotection during temozolomide treatment in combination with O6-benzylguanine, the inhibitor of MGMT, to permit dose escalation, resulting in surpassing of the median survival for patients with GBM with poor prognosis.28 In this study, conditioning with carmustine resulted in successful HSC engraftment. This evidence concerns the gene MGMT and glioblastoma.